Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4563364
Max Phase: Preclinical
Molecular Formula: C90H129N13O28S
Molecular Weight: 1873.15
Molecule Type: Unknown
Associated Items:
ID: ALA4563364
Max Phase: Preclinical
Molecular Formula: C90H129N13O28S
Molecular Weight: 1873.15
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1cccc2ccccc12)C(N)=O
Standard InChI: InChI=1S/C90H129N13O28S/c1-3-5-31-67(84(116)95-56-77(106)97-72(52-62-55-94-66-33-24-23-30-65(62)66)87(119)100-68(32-6-4-2)85(117)103-74(54-82(113)114)89(121)101-70(83(91)115)51-61-28-25-27-60-26-21-22-29-64(60)61)99-86(118)71(50-59-36-38-63(39-37-59)131-132(124,125)126)102-88(120)73(53-81(111)112)98-79(108)58-130-49-47-128-45-43-93-78(107)57-129-48-46-127-44-42-92-75(104)41-40-69(90(122)123)96-76(105)34-19-17-15-13-11-9-7-8-10-12-14-16-18-20-35-80(109)110/h21-30,33,36-39,55,67-74,94H,3-20,31-32,34-35,40-54,56-58H2,1-2H3,(H2,91,115)(H,92,104)(H,93,107)(H,95,116)(H,96,105)(H,97,106)(H,98,108)(H,99,118)(H,100,119)(H,101,121)(H,102,120)(H,103,117)(H,109,110)(H,111,112)(H,113,114)(H,122,123)(H,124,125,126)/t67-,68-,69-,70-,71-,72-,73-,74-/m0/s1
Standard InChI Key: IUSFSIDKWAJIKQ-CGOQMMCRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1873.15 | Molecular Weight (Monoisotopic): 1871.8791 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Sensfuss U, Kruse T, Skyggebjerg RB, Uldam HK, Vestergaard B, Huus K, Vinther TN, Reinau ME, Schéele S, Clausen TR.. (2019) Structure-Activity Relationships and Characterization of Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor Agonists., 62 (3): [PMID:30624060] [10.1021/acs.jmedchem.8b01558] |
Source(1):